Effective delivery of palliative radiotherapy: A prospective study

Clément-Zhao, A.; Luu, Michael; Bibault, Jean‐Emmanuel; Daveau, C.; Kreps, S.; Jaulmes, Hélène; Dessard-Diana, B.; Housset, M.; Giraud, P; Durdux, C.

doi:10.1016/j.canrad.2018.09.006

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, only four studies we extracted from reported the 30-day mortality rate for patients getting >= 10 fractions of PR treatment. Several studies also reported 30-day mortality rate based on total numbers of treatments given (one patient could have multiple treatments) [40,46,53,59] as opposed to reporting only the last treatment each patient received, the latter method being the outcome we used to assess fractionation and 30-day mortality rate. We did find that patients getting SBRT for brain metastases as a subgroup appeared to have a lower 30-day mortality rate after PR, which likely reflects the appropriate selection of patients with relatively good prognostic outlook for SBRT treatment.…”

Section: Discussionmentioning

confidence: 99%

Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis

Kutzko

Dadwal

Holt

et al. 2022

Radiotherapy and Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis

Kutzko

Dadwal

Holt

et al. 2022

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…This condition has a direct impact on survival and quality of life in ways that are dependent on proper pain management. The challenge is to find a balance between pain control and analgesia so that the patient remains independent enough to perform daily activities [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses

et al. 2023

View full text Add to dashboard Cite

177Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). 177Lu-DOTATOC is a patent-free radioligand, molecularly recognized by somatostatin receptors (SSTR-2) overexpressed in cancer cells of about 80% of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET). This translational research aimed to determine the efficacy and safety of 177Lu-iPSMA and 177Lu-DOTATOC developed as GMP pharmaceutical formulations for treating progressive and advanced mCRPC and NET. One hundred and forty-five patients with mCRPC and one hundred and eighty-seven subjects with progressive NET (83% GEP-NET and 17% other NET), treated with 177Lu-iPSMA and 177Lu-DOTATOC, respectively, were evaluated. Patients received a mean dose of 7.4 GBq per administration of 177Lu-iPSMA (range 1–5 administrations; 394 treatment doses) or 177Lu-DOTATOC (range 2–8 administrations; 511 treatment doses) at intervals of 1.5–2.5 months. Efficacy was assessed by SPECT/CT or PET/CT. Results were stratified by primary tumor origin and number of doses administered. Patients with mCRPC showed overall survival (OS) of 21.7 months with decreased radiotracer tumor uptake (SUV) and PSA level in 80% and 73% of patients, respectively. In addition, a significant reduction in pain (numerical scale from 10–7 to 3–1) was observed in 88% of patients with bone metastases between one and two weeks after the second injection. In the GEP-NET population, the median progression-free survival was 34.7 months, with an OS of >44.2 months. The treatments were well tolerated. Only ten patients experienced grade ≥ 3 myelosuppression (3% of all patients). The observed safety profiles and favorable therapeutic responses demonstrated the potential of 177Lu-iPSMA and 177Lu-DOTATOC to improve overall survival and quality of life in patients with progressive and advanced mCRPC and NET.

show abstract

“…Increasedsodium levels observed in cancer tissue, due to the persistent currents thatVGSCs develop under hypoxic conditions, have been correlated to tumor growth, invasiveness and metastasis [2]. Quality of life of bone metastasis patientssignificantly improves after radiotherapy (10 fractions of 3Gy or 1 fraction of8 Gy) due to the control of tumor spreading and the sustained pain relief [3, 4]. Mechanism trough which radiotherapy controls tumor spread and achieves painrelief is poorly understood.…”

mentioning

confidence: 99%

Stereotactic Radiosurgery Effect on Ion Channel Activity: Implications in Metastasis and Cancer Pain Relief

Azorín-Vega¹,

Picones²,

Moranchel

et al. 2020

The FASEB Journal

View full text Add to dashboard Cite

Influence of aberrantly expression ofvoltage‐gated sodium channels (VGSCs) in metabolic regulation, cell cycledistribution, proliferation, radioresistance and metastasis confirm their role incarcinogenesis. Recently VGSCs have been proposed as prognostic markers andantimetastatic targets with diagnostic and therapeutic potential [1]. Increasedsodium levels observed in cancer tissue, due to the persistent currents thatVGSCs develop under hypoxic conditions, have been correlated to tumor growth, invasiveness and metastasis [2]. Quality of life of bone metastasis patientssignificantly improves after radiotherapy (10 fractions of 3Gy or 1 fraction of8 Gy) due to the control of tumor spreading and the sustained pain relief [3, 4]. Mechanism trough which radiotherapy controls tumor spread and achieves painrelief is poorly understood. In the present work the role of VGSCs in tumorcontrol and pain relief mechanisms after irradiation were analyzed by invasionassays and whole‐cell patch clamp. Monolayers of NaV1.7 expressing and wildtype CHO cells were irradiated in a LINAC. SL 15 Phillips (8X8 cm2 field, 6MV xrays, gantry 180°) before evaluating the clonal and invasive capacity of cellsand the function of NaV1.7. Resuls show that NaV1.7 expression reduces CHOcells plating efficiency and confers radioresistance. Irradiation reduces sodiumcurrent density and increased the voltage to hyperpolarize. Apparently, irradiationdelayed NaV1.7 activation and significantly abolished invasiveness induced byradiotherapy. Support or Funding Information This study was performed as part of the activities of the “Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos‐CONACyT”. Grant 293334. NaV1.7 expression reduces CHO cells plating efficiency and confers radioresistance NaV1.7 expression (red line) confers radioresistance to CHO cells (black line) In Vivo Evidence for Voltage-GatedSodium Channel Expression in Carcinomas and Potentiation of MetastasisMBA.DjamgozSP.FraserWJ.BrackenburyCancers(Basel)1111E1675E1695Colorectal cancer invasiveness in vitro: Predominantcontribution of neonatal Nav1.5 under normoxia and hypoxiaRM.GuzelK.OgmenKMIlievaSP.FraserMBA.DjamgozJ. Cell. Physiol.23465826593Needs assessment of primary care physicians in the management ofchronic pain in cancer survivorsR.ChowK.SaundersH.BurkeA.BelangerE.ChowSupport Care Cancer1135053514Effective delivery of palliative radiotherapy: A prospectivestudyA.Clément-ZhaoM.LuuJE.BibaultC.DaveauS.KrepsH.JaulmesB.Dessard-DianaM.HoussetP.GiraudC.DurduxCancer Radiother235365369

show abstract

Effective delivery of palliative radiotherapy: A prospective study

Cited by 4 publications

References 27 publications

Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis

Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses

Stereotactic Radiosurgery Effect on Ion Channel Activity: Implications in Metastasis and Cancer Pain Relief

Contact Info

Product

Resources

About